Citizens Financial Group Inc. RI Makes New Investment in Organon & Co. $OGN

Citizens Financial Group Inc. RI bought a new stake in Organon & Co. (NYSE:OGN) during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 55,206 shares of the company’s stock, valued at approximately $331,000.

A number of other institutional investors have also modified their holdings of the stock. Royal Bank of Canada grew its position in Organon & Co. by 53.4% in the 1st quarter. Royal Bank of Canada now owns 360,862 shares of the company’s stock valued at $5,374,000 after buying an additional 125,648 shares during the last quarter. Goldman Sachs Group Inc. raised its position in Organon & Co. by 126.4% during the 1st quarter. Goldman Sachs Group Inc. now owns 1,435,198 shares of the company’s stock worth $21,370,000 after buying an additional 801,307 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its position in Organon & Co. by 2.6% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,042,991 shares of the company’s stock worth $15,530,000 after buying an additional 26,640 shares during the last quarter. Focus Partners Wealth lifted its stake in shares of Organon & Co. by 33.2% in the 1st quarter. Focus Partners Wealth now owns 55,875 shares of the company’s stock worth $832,000 after acquiring an additional 13,925 shares during the period. Finally, XTX Topco Ltd acquired a new stake in shares of Organon & Co. in the 2nd quarter worth $107,000. Institutional investors and hedge funds own 77.43% of the company’s stock.

Insider Buying and Selling

In related news, SVP Lynette Holzbaur bought 26,448 shares of the stock in a transaction on Wednesday, May 6th. The shares were bought at an average cost of $13.35 per share, for a total transaction of $353,080.80. Following the completion of the transaction, the senior vice president owned 52,851 shares of the company’s stock, valued at $705,560.85. This represents a 100.17% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 1.62% of the company’s stock.

Organon & Co. Price Performance

Organon & Co. stock opened at $13.51 on Friday. Organon & Co. has a one year low of $5.69 and a one year high of $13.60. The company has a debt-to-equity ratio of 9.47, a quick ratio of 1.42 and a current ratio of 1.97. The business has a fifty day moving average of $13.44 and a two-hundred day moving average of $9.96. The company has a market cap of $3.55 billion, a P/E ratio of 14.52, a price-to-earnings-growth ratio of 1.25 and a beta of 1.54.

Organon & Co. (NYSE:OGN) last issued its earnings results on Thursday, April 30th. The company reported $0.71 EPS for the quarter, missing the consensus estimate of $0.83 by ($0.12). The company had revenue of $1.46 billion for the quarter, compared to analysts’ expectations of $1.49 billion. Organon & Co. had a return on equity of 99.95% and a net margin of 3.99%.Organon & Co.’s revenue for the quarter was down 3.5% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.02 earnings per share. As a group, analysts predict that Organon & Co. will post 3.23 earnings per share for the current fiscal year.

Organon & Co. Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Thursday, June 11th. Investors of record on Monday, May 11th were issued a dividend of $0.02 per share. The ex-dividend date of this dividend was Monday, May 11th. This represents a $0.08 dividend on an annualized basis and a yield of 0.6%. Organon & Co.’s payout ratio is currently 8.60%.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on the stock. BNP Paribas Exane reaffirmed a “neutral” rating and issued a $14.00 target price (up from $12.00) on shares of Organon & Co. in a report on Wednesday, April 29th. Weiss Ratings raised shares of Organon & Co. from a “hold (c-)” rating to a “hold (c)” rating in a report on Monday. Piper Sandler upgraded shares of Organon & Co. from an “underweight” rating to a “neutral” rating and raised their price objective for the company from $5.00 to $14.00 in a research report on Tuesday, April 28th. Finally, Zacks Research raised Organon & Co. from a “strong sell” rating to a “hold” rating in a report on Tuesday, April 14th. Five analysts have rated the stock with a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Reduce” and an average price target of $11.40.

About Organon & Co.

Organon & Co is a global healthcare company that was established as an independent, publicly traded entity following its spin-off from Merck & Co in June 2021. Headquartered in Jersey City, New Jersey, Organon focuses on delivering therapeutic solutions across women’s health, biosimilars, and established brands. The company’s creation reflected a strategic effort to concentrate on specialty pharmaceuticals and legacy products with proven patient impact.

In women’s health, Organon provides a broad portfolio of products addressing reproductive and gynecological conditions, including fertility treatments, contraception, and hormone replacement therapies.